Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Early DOAC therapy after invasive acute pulmonary embolism therapy: fast track PE?
Session:
SESSÃO DE POSTERS 37 - DOENÇAS CARDIOVASCULARES - TERAPÊUTICA ANTITROMBÓTICA
Speaker:
Débora Da Silva Correia
Congress:
CPC 2025
Topic:
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
Theme:
14. Acute Cardiac Care
Subtheme:
14.3 Acute Cardiac Care – CCU, Intensive, and Critical Cardiovascular Care
Session Type:
Cartazes
FP Number:
---
Authors:
Débora Da Silva Correia; Rita Barbosa; Rita Bello; João Brito; Afonso Felix de Oliveira; João Presume; Christopher Strong; Catarina Brízido; António Tralhão; Sílvio Leal; Manuel de Sousa Almeida; Pedro Adragão
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><u>[Introduction]:</u> Percutaneous invasive therapies, including catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT), have emerged as treatment options for high-risk and selected intermediate high-risk PE. Patients undergoing these procedures were excluded from the landmark DOAC trials, so the safety and efficacy of early DOAC therapy in this setting remains unexplored. We aimed to access these outcomes in a cohort of invasively treated PE patients.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><u><span style="font-size:10.0pt">[Methods]</span></u><span style="font-size:10.0pt">: R</span>etrospective cohort study analysing PE patients who underwent CDT and/or MT at a tertiary centre from 2020 to 2024. Patients were grouped based on the timing of DOAC initiation: within 24 hours (group 1), between 24-48 hours (group 2), and after 48 hours (group 3). The primary safety outcome was major bleeding events according to International Society on Thrombosis and Haemostasis (ISTH) criteria, and the primary effectiveness outcome was venous thromboembolism recurrence.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><u>[Results]:</u> A total of 74 patients (mean age 59±16 years; 43% male) underwent percutaneous interventions for PE, 47% with MT, 26% with CDT using recombinant tissue-type plasminogen activator (rt-PA), and 27% with both. All patients received unfractionated heparin post-procedure. A total of 14 patients initiated DOAC (apixaban or rivaroxaban) within 24 hours, and 11 additional patients within 48 hours-<em>Figure 1</em>. No significant baseline differences were observed between groups, except for higher admission haemoglobin in Group 1 and male gender in group 2 (<em>Table 1</em>). However, group 3 had more patients with syncope or cardiac arrest, and higher PESI scores and NTproBNP levels. Systemic rt-PA was administered in 1 patient in group 2 and 5 patients in group 3 (p=0.47). The type of invasive PE therapy was comparable across groups.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">The low number of bleeding complications (9 major bleeding events), occurred mostly in group 3, and all during index hospitalization. At 30-days follow-up, no venous thrombosis recurrence had occurred. Patients on group 1 experienced a significantly shorter hospital stay compared to those on group 3 (5 days [3-7] vs 10 days [6-14], p<0.001). No differences were noted between groups 1 and 2.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">On multivariate analysis, female sex, higher systolic blood pressure, and the absence of a saddle thrombus were identified as predictors of an early switch to DOAC within the first 48 hours (<em>Table 2</em>).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><u>[Conclusion]:</u> Early initiation of DOACs following MT and/or CDT for acute PE appears to be a safe approach. Moreover, no signs of lower efficacy were raised by this analysis, and is additionally associated with a shorter hospital stay. Patient selection criteria for this treatment strategy should be further analysed, to allow shorter hospitalizations and improve patient outcomes. </span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site